CeriBell’s (CBLL) Buy Rating Reaffirmed at BTIG Research

CeriBell (NASDAQ:CBLL)‘s stock had its “buy” rating reaffirmed by BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $28.00 price objective on the stock. BTIG Research’s price objective points to a potential upside of 45.08% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group lowered their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.80.

CeriBell Trading Up 2.6%

CeriBell stock opened at $19.30 on Tuesday. CeriBell has a one year low of $10.85 and a one year high of $24.33. The business’s fifty day moving average is $18.55 and its 200 day moving average is $19.08. The stock has a market capitalization of $732.30 million, a PE ratio of -11.84 and a beta of 0.81. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The company had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. On average, sell-side analysts predict that CeriBell will post -1.69 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the completion of the transaction, the insider directly owned 3,765,054 shares in the company, valued at approximately $75,752,886.48. The trade was a 5.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William W. Burke sold 2,207 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total transaction of $43,786.88. Following the sale, the director owned 23,022 shares in the company, valued at approximately $456,756.48. The trade was a 8.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 300,685 shares of company stock worth $5,935,326 in the last quarter. Company insiders own 17.70% of the company’s stock.

Institutional Trading of CeriBell

Several institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after buying an additional 374,179 shares in the last quarter. Rhumbline Advisers raised its holdings in CeriBell by 109.9% during the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after acquiring an additional 17,177 shares during the period. New York State Common Retirement Fund raised its holdings in CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after acquiring an additional 5,200 shares during the period. Quantbot Technologies LP lifted its position in shares of CeriBell by 70.3% in the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after acquiring an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. bought a new position in shares of CeriBell in the second quarter worth about $197,000.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: The FDA granted 510(k) clearance for two AI enhancements to CeriBell’s cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. The features are designed to help neurologists identify abnormal EEG patterns, reduce signal interference and review critical-care recordings more efficiently. The update expands the functionality of CeriBell’s existing point-of-care brain-monitoring system without requiring software downtime or installation. CeriBell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction
• Positive Sentiment: Second-quarter revenue rose to $28.1 million, exceeding the $27.28 million analyst consensus. Management maintained full-year 2026 revenue guidance of $114 million to $117 million, with the low end in line with consensus, suggesting continued demand for the company’s neurological monitoring platform. CeriBell Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings call highlighted the newly cleared AI tools and the company’s focus on improving clinical workflows and adoption of its point-of-care EEG system. The commercial benefit of the enhancements will depend on hospital uptake, clinical acceptance and the company’s ability to convert the technology into incremental revenue. CeriBell Q2 2026 Earnings Call Transcript
• Negative Sentiment: CeriBell reported a second-quarter loss of $0.51 per share, wider than the $0.45-$0.47 consensus range and worse than the $0.38 loss recorded a year earlier. The company remains unprofitable, increasing investor focus on operating leverage and the pace at which revenue growth can offset expenses. CeriBell Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Reported insider-trading data shows 44 open-market sales and no purchases over the past six months, including sales by senior executives. While such transactions may reflect personal or equity-compensation decisions, the lack of insider buying is a potential sentiment headwind.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.